Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

Overview of attention for article published in Molecular Cancer Therapeutics, June 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 9 news stories from 9 outlets.

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update - Recently-announced company…

- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated…

News provided by CytomX Therapeutics Inc. Aug 04, 2022, 4:15 PM ET - Recently-announced company restructuring focuses internal…

CytomX Therapeutics Inc. - Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 5 additional news stories.